Sign inJoin waitlistJoin the waitlist

Heather Wakelee

Deputy Director · Stanford Health Care

Credentials: · · ·

History

Stanford Health Care
Present
Division of Oncology · Stanford Health Care
Present
Division of Oncology · New York Presbyterian Hospital
Present

Medical Oncology
Stanford University Division of Oncology (2003) CA
2000–2003
Stanford University
1996–1999
Johns Hopkins Univ Sch of Med
1992–1996

Research

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Nature Medicine · 2014 · 1,763 citations
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
The Lancet · 2021 · 1,283 citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Annals of Oncology · 2019 · 1,133 citations

Joel Neal
140 papers · 2 as a fellow
Sukhmani Padda
62 papers
Maximilian Diehn
46 papers
Millie Das
41 papers · 1 as a fellow
JA
Jacqueline Aredo
33 papers · 31 as a resident
Jonathan Riess
33 papers · 4 as a fellow
Kavitha Ramchandran
32 papers
Billy Loo
31 papers · 1 as a resident
Nathaniel Myall
28 papers · 4 as a fellow
David Gandara
25 papers · 3 as a fellow
Lecia Sequist
21 papers
Joseph Shrager
19 papers

Grants

Stanford University NCTN- Network Lead Academic Site
National Cancer Institute · U10
Contact PI · $2.8M · Stanford University
2014–2019
Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles
National Cancer Institute · R33
PI · $738.1K · Stanford University
2010–2013
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $910 · Stanford University
2007–2008

Clinical trials

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Stanford University
2018–2022
Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer
Principal investigator · Terminated · Phase 1
ACEA Therapeutics, Inc.
2015–2019
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Principal investigator · Terminated · Phase 1
Heather Wakelee
2012–2014
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
Principal investigator · Terminated · Phase 1
Stanford University
2012–2013